CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

Ingrid Boere; Ignace Vergote; Rob Hanssen; Mathilde Jalving; Christine Gennigens; Petronella Ottevanger; Yes J van de Wouw; Cristianne J F Rijcken; Ron H J Mathijssen; Jonathan Ledermann

doi:10.1136/ijgc-2023-004308

Article info

other Versions

You are currently viewing an earlier version of this article (August 07, 2023).
View the most recent version of this article

Original research

CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

Authors

Ingrid Boere Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands PubMed articles Google scholar articles
Ignace Vergote Division of Gynaecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium PubMed articles Google scholar articles
Rob Hanssen Cristal Therapeutics, Maastricht, The Netherlands PubMed articles Google scholar articles
Mathilde Jalving Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands PubMed articles Google scholar articles
Christine Gennigens Department of Medical Oncology, CHU de Liège, Liège, Belgium PubMed articles Google scholar articles
Petronella Ottevanger Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands PubMed articles Google scholar articles
Yes J van de Wouw Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands PubMed articles Google scholar articles
Cristianne J F Rijcken Cristal Therapeutics, Maastricht, The Netherlands PubMed articles Google scholar articles
Ron H J Mathijssen Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands PubMed articles Google scholar articles
Jonathan Ledermann Department of Oncology, University College London (UCL) Cancer Institute, UCL & UCL Hospitals Comprehensive Biomedical Research Centre, London, UK PubMed articles Google scholar articles

Correspondence to Dr Ingrid Boere, Cancer Institute Department of Medical Oncology, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands; i.boere{at}erasmusmc.nl

View Full Text

Citation

Boere I, Vergote I, Hanssen R, et al

CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer

International Journal of Gynecologic Cancer Published Online First: 17 April 2023. doi: 10.1136/ijgc-2023-004308

Publication history

Received January 22, 2023
Accepted April 6, 2023
First published April 17, 2023.

Article Versions

You are currently viewing a Previous version of this article (7 August 2023).
View the most recent version of this article

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password